New insider activity at Spero Therapeutics ( (SPRO) ) has taken place on September 3, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Ankit Mahadevia has recently sold 6,572 shares of Spero Therapeutics stock, amounting to a transaction value of $12,946.
Recent Updates on SPRO stock
Spero Therapeutics has recently reported significant progress in its Phase III PIVOT-PO trial for Tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, which was stopped early due to efficacy. This success, along with a strategic partnership with GSK, positions the company well for future FDA submissions and potential commercialization. Financially, Spero has shown improved performance with increased revenue and reduced net loss, primarily due to collaboration revenue from GSK, extending its cash runway into 2028. However, the company faces challenges with its SPR720 program, which did not meet its primary endpoint, presenting potential safety concerns. Despite these mixed developments, the company’s financial and strategic positioning remains strong, with a focus on advancing its clinical programs.
Spark’s Take on SPRO Stock
According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.
Spero Therapeutics is currently facing significant financial and operational challenges, as evidenced by declining revenues, negative profit margins, and operational inefficiencies. Technical analysis suggests ongoing bearish momentum, while valuation metrics highlight financial struggles due to a negative P/E ratio. The earnings call highlighted promising developments in their tebipenem HBr program, but these are offset by setbacks in other trials and increased financial losses. The overall score reflects these mixed but predominantly negative factors.
To see Spark’s full report on SPRO stock, click here.
More about Spero Therapeutics
YTD Price Performance: 89.81%
Average Trading Volume: 1,066,387
Technical Sentiment Signal: Buy
Current Market Cap: $116.5M